Study Shows MRI Can Detect Breast Disease Missed by Mammography

News
Article
OncologyONCOLOGY Vol 20 No 4
Volume 20
Issue 4

Researchers have found that mammography coupled with magnetic resonance imaging (MRI) is extremely sensitive in the detection of ductal carcinoma in situ (DCIS).

Researchers have found that mammography coupled with magnetic resonance imaging (MRI) is extremely sensitive in the detection of ductal carcinoma in situ (DCIS). The recent study, which was published in The Breast Journal (11[6]:382-390, 2005), examined the medical records of women diagnosed with DCIS, aged 34 to 79 years, who underwent MRI and mammographic examinations over approximately 2 years.

The results revealed 39 sites of pure DCIS in 33 breasts of 32 women. In each of these women, both MRI and mammograms were performed prior to surgery. Of the 33 breasts involved, DCIS was detected by MRI alone in 64%, and detected by mammography alone in only 3%. MRI and mammography together detected DCIS in 24% of breasts; in 9%, DCIS was found at mastectomy but the mammogram and MRI were negative. The nuclear grade of DCIS detected by MRI and mammography was similar, although the size of lesions identified by MRI was larger. Breast density did not affect the results.

Recommendations

"The results from our small, select group of patients suggest that in women with known or suspected DCIS, determination of the presence and extent of disease may be best established with mammography complemented by MRI," concluded the researchers, led by Jennifer Menell, md, Memorial Sloan-Kettering Cancer Center.

The American Cancer Society recommends that women age 40 and older should have a mammogram every year and that those at increased risk should talk with their doctors about the benefits and limitations of starting mammograms when they are younger, having additional tests (such as MRI), or having more frequent exams.

Recent Videos
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Related Content